Revised PORT recommendations

Same author

A translational neuroscience & computational evaluation of a D1R partial agonist for schizophrenia (TRANSCENDS): Rationale and study design of a brain-based clinical trial.

Journal of psychiatric research·2026

Same author

A Translational Neuroscience & Computational Evaluation of a D1R Partial Agonist for Schizophrenia (TRANSCENDS): Rationale and Study Design of a Brain-Based Clinical Trial.

medRxiv : the preprint server for health sciences·2025

Same author

Preventing disease progression in schizophrenia: What are we waiting for.

Journal of psychiatric research·2025

Same author

Changes in Rates of Suicide by Mass Shooters, 1980-2019.

Archives of suicide research : official journal of the International Academy for Suicide Research·2024

Same author

Analysis of schizophrenia-associated genetic markers in the HLA region as risk factors for tardive dyskinesia.

Human psychopharmacology·2024

Same author

Is schizophrenia neurodevelopmental, neurodegenerative or something else: A reply to Murray et al. (2022).

Schizophrenia research·2023

Same journal

Metabolic Improvements with a Ketogenic Diet Correlate with Symptom Improvement in Psychosis: A Randomized Controlled Trial.

Schizophrenia bulletin·2026

Same journal

Reconsidering the Term "Treatment Resistant Schizophrenia".

Schizophrenia bulletin·2026

Same journal

The Effect of Semaglutide on Antipsychotic-Induced Weight Gain and Other Metabolic Parameters, among a Cohort of Inpatients.

Schizophrenia bulletin·2026

Same journal

Comparing Apples to Oranges Obscures Tortoises Beating Hares: The Relationship Between Rate of Antipsychotic Tapering and Relapse.

Schizophrenia bulletin·2026

Same journal

Beyond the Need for Speed: D2 Receptor Affinity Predicts Relapse after Antipsychotic Tapering in First Episode Psychosis.

Schizophrenia bulletin·2026

Same journal

Correction to: The Mini-CAARMS: Development and Validation of a Short Version of the Comprehensive Assessment of AT Risk Mental States to Facilitate Preventive Psychiatry.

Schizophrenia bulletin·2026

Related Experiment Videos

Revised PORT recommendations

Related Concept Videos

A translational neuroscience & computational evaluation of a D1R partial agonist for schizophrenia (TRANSCENDS): Rationale and study design of a brain-based clinical trial.

A Translational Neuroscience & Computational Evaluation of a D1R Partial Agonist for Schizophrenia (TRANSCENDS): Rationale and Study Design of a Brain-Based Clinical Trial.

Preventing disease progression in schizophrenia: What are we waiting for.

Changes in Rates of Suicide by Mass Shooters, 1980-2019.

Analysis of schizophrenia-associated genetic markers in the HLA region as risk factors for tardive dyskinesia.

Is schizophrenia neurodevelopmental, neurodegenerative or something else: A reply to Murray et al. (2022).

Metabolic Improvements with a Ketogenic Diet Correlate with Symptom Improvement in Psychosis: A Randomized Controlled Trial.

Reconsidering the Term "Treatment Resistant Schizophrenia".

The Effect of Semaglutide on Antipsychotic-Induced Weight Gain and Other Metabolic Parameters, among a Cohort of Inpatients.

Comparing Apples to Oranges Obscures Tortoises Beating Hares: The Relationship Between Rate of Antipsychotic Tapering and Relapse.

Beyond the Need for Speed: D2 Receptor Affinity Predicts Relapse after Antipsychotic Tapering in First Episode Psychosis.

Correction to: The Mini-CAARMS: Development and Validation of a Short Version of the Comprehensive Assessment of AT Risk Mental States to Facilitate Preventive Psychiatry.

Related Experiment Videos

Revised PORT recommendations

Related Concept Videos

Related Articles

A translational neuroscience & computational evaluation of a D1R partial agonist for schizophrenia (TRANSCENDS): Rationale and study design of a brain-based clinical trial.

A Translational Neuroscience & Computational Evaluation of a D1R Partial Agonist for Schizophrenia (TRANSCENDS): Rationale and Study Design of a Brain-Based Clinical Trial.

Preventing disease progression in schizophrenia: What are we waiting for.

Changes in Rates of Suicide by Mass Shooters, 1980-2019.

Analysis of schizophrenia-associated genetic markers in the HLA region as risk factors for tardive dyskinesia.

Is schizophrenia neurodevelopmental, neurodegenerative or something else: A reply to Murray et al. (2022).

Metabolic Improvements with a Ketogenic Diet Correlate with Symptom Improvement in Psychosis: A Randomized Controlled Trial.

Reconsidering the Term "Treatment Resistant Schizophrenia".

The Effect of Semaglutide on Antipsychotic-Induced Weight Gain and Other Metabolic Parameters, among a Cohort of Inpatients.

Comparing Apples to Oranges Obscures Tortoises Beating Hares: The Relationship Between Rate of Antipsychotic Tapering and Relapse.

Beyond the Need for Speed: D2 Receptor Affinity Predicts Relapse after Antipsychotic Tapering in First Episode Psychosis.

Correction to: The Mini-CAARMS: Development and Validation of a Short Version of the Comprehensive Assessment of AT Risk Mental States to Facilitate Preventive Psychiatry.